Axis 1, Team 6 | Modifications during cancer progression

Our axis 1 focuses on gene expression and epigenetic modifications during cancer progression.

pcna fhl2
Axis 1 picture legend - Two phenotypes coexist in cancerous cell populations: a proliferative state, illustrated by the red nuclear staining of PCNA ("Proliferation antigen") and a mesenchymal states, illustrated by the staining in green of the metastasis marker FHL2. Note that the staining are mutually exclusive, which means that a cell can not at the same time divide and migrate.

Breast cancer is the most common cancer in women, with more than 50 000 new cases every year in France and about 1 in 8 women affected.
Estrogen receptors (ER) are closely associated with hormone-dependent breast cancer and it is well established that prolonged exposure to endogenous or exogenous estrogens (E2) is one of the first etiological factors in these cancers. At least 70% of breast cancers are ER positive and are under the influence of the mitogenic effects of E2. Hormone therapy is the most effective treatment used to treat ER-positive breast cancers. Unfortunately, a significant proportion of breast cancers are resistant to hormone therapy or develop an anti-estrogen (tamoxifen) resistance. Our research aims at understanding the origin of this hormonal effects and the underlying transcriptional and epigenetic mechanisms.